
Matt Dixon joined Compass Carter Osborne in 2023 to enhance our presence in the Life Sciences sector. He has over eight years of experience partnering with listed and PE backed Pharma, Biotech, MedTech and Pharma Services firms across EMEA and North America with a focus on C-Suite and senior leadership mandates.
Example placements include, but are not limited to, Managing Director, General Manager and other P&L ownership positions. He has also completed VP searches in Strategy, Commercial, Clinical, Medical, Regulatory and Technical Operations functions.
CEO | NK:IO | VC backed
Head of Business Development, Biologics | Curia | International Investors
VP Managing Director | Eurofins Gold Standard Diagnostics | Public